Prescient Therapeutics Limited

As of June 30, 2026, Prescient Therapeutics Limited carries a market capitalization of 64.14M, placing it among publicly traded companies globally. Its enterprise value stands at 55.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Prescient Therapeutics Limited's next confirmed earnings release is scheduled for February 19, 2027.

As of June 30, 2026, Prescient Therapeutics Limited has 1.05B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Prescient Therapeutics Limited maintains a current ratio of 7.14, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.57, indicating elevated leverage, while an interest coverage ratio of -989.90 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Prescient Therapeutics Limited posted a negative return on equity (ROE) of -54.73, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.41, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Prescient Therapeutics Limited's stock has gained approximately 27.27% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -10.59M, while operating income came in at -10.59M.

As of June 30, 2026, Prescient Therapeutics Limited holds 9.05M in cash and equivalents against 222,971.00 in total debt, resulting in a net debt position of -9.03M. Total book value stands at 14.20M, with working capital of 12.06M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -14.56, meaning Prescient Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Prescient Therapeutics Limited's most recent stock split took place on March 28, 2019 with a 55:56 split ratio.